Davidson Ben
Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, N-0310 Oslo, Norway; University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, N-0316 Oslo, Norway.
Hum Pathol. 2015 Jun;46(6):789-804. doi: 10.1016/j.humpath.2015.02.006. Epub 2015 Feb 28.
Malignant pleural mesothelioma (MPM) is a clinically aggressive tumor originating from mesothelial cells, which line the serosal cavities. Recent years have seen extensive research aimed at identifying new therapeutic targets, predictive markers and prognostic factors in this disease. These include both serum and tissue markers, and are related to multiple cellular pathways which affect cell survival, proliferation, apoptosis, angiogenesis, interaction with the immune response and DNA repair. Several of these molecules may become relevant for pathologists as part of the effort to select patient sub-populations for targeted therapy in the future. This review summarizes current data in this area and discusses their potential clinical relevance.
恶性胸膜间皮瘤（MPM）是一种起源于衬覆浆膜腔的间皮细胞的临床侵袭性肿瘤。近年来，针对该疾病中新型治疗靶点、预测标志物和预后因素开展了广泛研究。这些包括血清和组织标志物，且与影响细胞存活、增殖、凋亡、血管生成、与免疫反应的相互作用及DNA修复的多种细胞途径相关。作为未来为靶向治疗选择患者亚群努力的一部分，这些分子中的几种可能对病理学家具有重要意义。本综述总结了该领域的当前数据，并讨论了它们潜在的临床相关性。
